A study reveals semaglutide may alleviate knee osteoarthritis pain in obese patients, highlighting its potential beyond ...

Whether millions gain access to breakthrough anti-obesity treatments may depend on Kennedy, Mehmet Oz and other key players ...

Few companies garner as much reliable attention as Novo Nordisk ( NVO) does these days. With a bull market coinciding with a ...

But basically it’s all about hitting the brain’s satiety centres. The new drugs make you feel full much more quickly and ...

But for a long time China’s people struggled to get hold of Wegovy because the country’s regulators had not approved it. Some ...

The biggest threat for European pharmaceutical groups currently comes from the United States. President-elect Donald Trump ...

The U.S. Centers for Medicare and Medicaid Services (CMS) on Tuesday, Nov. 26, announced proposed changes in Medicare and Medicaid that would formally recognize obesity as a disease, meaning ...

Novo Nordisk shifts its recruitment focus to China, expanding operations to meet rising demand for Ozempic and Wegovy in the ...

NEW YORK (Reuters) - The U.S. pharmaceutical industry is pushing to revamp the new law that allows Medicare to negotiate prices for its costliest prescription drugs once president-elect Donald Trump ...

The Biden administration wants to expand coverage of anti-obesity medications to millions on Medicare, Medicaid.

Mounjaro is a treatment for Type 2 diabetes that activates GIP and GLP-1 pathways to help regulate blood sugar. It’s part of ...

The Department of Health and Human Services seeks to expand when Medicare and Medicaid can cover anti-obesity drugs, such as ...